A randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the safety and efficacy of FK962 in subjects with mild to moderate Alzheimer's disease

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the safety and efficacy of FK962 in subjects with mild to moderate Alzheimer's disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs FK 962 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2006 Status change
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top